
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. exhibits a positive financial outlook driven by a meaningful increase in Chromium reaction volumes, indicating a robust market for its integrated solutions in analyzing biological systems. Despite ongoing pricing pressure, the company has seen consumable sales growth outpacing instrument revenue, with projections suggesting a potential increase of 5 to 19 times in consumables by platform by 2027. The firm's diverse product offerings and strong geographical revenue foundation, primarily from the United States, further reinforce its competitive position in the life science technology sector.
Bears say
10x Genomics is facing significant challenges, evidenced by a contraction in 2024 marked by double-digit pricing pressure and stagnant to declining volumes, with growth projections not anticipated to improve until 2027. The company's fourth-quarter earnings revealed a notable miss in expected EPS and a full-year revenue outlook that fell short of market expectations, indicating ongoing operational difficulties. As a result, despite recent market expansions, 10x Genomics has experienced a decline of over 90% in stock value since its peak in 2021, reflecting investor disappointment and lack of confidence in its recovery trajectory.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares